vs

Side-by-side financial comparison of MIMEDX GROUP, INC. (MDXG) and PAMT CORP (PAMT). Click either name above to swap in a different company.

PAMT CORP is the larger business by last-quarter revenue ($141.3M vs $118.1M, roughly 1.2× MIMEDX GROUP, INC.). MIMEDX GROUP, INC. runs the higher net margin — 12.9% vs -20.7%, a 33.6% gap on every dollar of revenue. On growth, MIMEDX GROUP, INC. posted the faster year-over-year revenue change (27.1% vs -15.1%). Over the past eight quarters, MIMEDX GROUP, INC.'s revenue compounded faster (18.1% CAGR vs -12.0%).

MiMedx is an American biomedical company based in Marietta, Georgia, founded in 2008. Using tissues from birth such as the placenta, amniotic sac, and umbilical cord, MiMedx creates skin for skin grafts for medical use.

MDXG vs PAMT — Head-to-Head

Bigger by revenue
PAMT
PAMT
1.2× larger
PAMT
$141.3M
$118.1M
MDXG
Growing faster (revenue YoY)
MDXG
MDXG
+42.3% gap
MDXG
27.1%
-15.1%
PAMT
Higher net margin
MDXG
MDXG
33.6% more per $
MDXG
12.9%
-20.7%
PAMT
Faster 2-yr revenue CAGR
MDXG
MDXG
Annualised
MDXG
18.1%
-12.0%
PAMT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MDXG
MDXG
PAMT
PAMT
Revenue
$118.1M
$141.3M
Net Profit
$15.2M
$-29.3M
Gross Margin
83.9%
Operating Margin
17.8%
-27.0%
Net Margin
12.9%
-20.7%
Revenue YoY
27.1%
-15.1%
Net Profit YoY
104.2%
7.4%
EPS (diluted)
$0.10
$-1.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MDXG
MDXG
PAMT
PAMT
Q4 25
$118.1M
$141.3M
Q3 25
$113.7M
$150.3M
Q2 25
$98.6M
$151.1M
Q1 25
$88.2M
$155.3M
Q4 24
$92.9M
$166.5M
Q3 24
$84.1M
$182.6M
Q2 24
$87.2M
$182.9M
Q1 24
$84.7M
$182.6M
Net Profit
MDXG
MDXG
PAMT
PAMT
Q4 25
$15.2M
$-29.3M
Q3 25
$16.7M
$-5.6M
Q2 25
$9.6M
$-9.6M
Q1 25
$7.0M
$-8.1M
Q4 24
$7.4M
$-31.6M
Q3 24
$8.1M
$2.4M
Q2 24
$17.6M
$-2.9M
Q1 24
$9.3M
$281.0K
Gross Margin
MDXG
MDXG
PAMT
PAMT
Q4 25
83.9%
Q3 25
83.5%
Q2 25
81.1%
Q1 25
81.2%
Q4 24
81.8%
Q3 24
81.8%
Q2 24
83.0%
Q1 24
84.7%
Operating Margin
MDXG
MDXG
PAMT
PAMT
Q4 25
17.8%
-27.0%
Q3 25
19.5%
-3.8%
Q2 25
12.5%
-7.3%
Q1 25
9.4%
-5.9%
Q4 24
11.9%
-22.6%
Q3 24
13.3%
1.3%
Q2 24
26.9%
-0.4%
Q1 24
15.6%
-0.4%
Net Margin
MDXG
MDXG
PAMT
PAMT
Q4 25
12.9%
-20.7%
Q3 25
14.7%
-3.7%
Q2 25
9.8%
-6.4%
Q1 25
8.0%
-5.2%
Q4 24
8.0%
-19.0%
Q3 24
9.6%
1.3%
Q2 24
20.2%
-1.6%
Q1 24
10.9%
0.2%
EPS (diluted)
MDXG
MDXG
PAMT
PAMT
Q4 25
$0.10
$-1.38
Q3 25
$0.11
$-0.27
Q2 25
$0.06
$-0.46
Q1 25
$0.05
$-0.37
Q4 24
$0.05
$-1.44
Q3 24
$0.05
$0.11
Q2 24
$0.12
$-0.13
Q1 24
$0.06
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MDXG
MDXG
PAMT
PAMT
Cash + ST InvestmentsLiquidity on hand
$166.1M
$83.7M
Total DebtLower is stronger
$18.0M
$333.9M
Stockholders' EquityBook value
$256.5M
$210.5M
Total Assets
$342.7M
$697.9M
Debt / EquityLower = less leverage
0.07×
1.59×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MDXG
MDXG
PAMT
PAMT
Q4 25
$166.1M
$83.7M
Q3 25
$142.1M
$115.6M
Q2 25
$118.9M
$117.3M
Q1 25
$106.4M
$102.7M
Q4 24
$104.4M
$110.7M
Q3 24
$88.8M
$92.3M
Q2 24
$69.0M
$114.0M
Q1 24
$48.5M
$125.8M
Total Debt
MDXG
MDXG
PAMT
PAMT
Q4 25
$18.0M
$333.9M
Q3 25
Q2 25
Q1 25
Q4 24
$19.0M
$325.6M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
MDXG
MDXG
PAMT
PAMT
Q4 25
$256.5M
$210.5M
Q3 25
$238.9M
$239.5M
Q2 25
$216.6M
$244.9M
Q1 25
$202.8M
$269.6M
Q4 24
$193.1M
$277.5M
Q3 24
$181.0M
$308.9M
Q2 24
$168.0M
$306.7M
Q1 24
$155.7M
$314.6M
Total Assets
MDXG
MDXG
PAMT
PAMT
Q4 25
$342.7M
$697.9M
Q3 25
$319.0M
$715.2M
Q2 25
$291.1M
$707.9M
Q1 25
$270.4M
$712.6M
Q4 24
$263.9M
$741.7M
Q3 24
$243.9M
$756.7M
Q2 24
$230.2M
$733.5M
Q1 24
$221.7M
$746.4M
Debt / Equity
MDXG
MDXG
PAMT
PAMT
Q4 25
0.07×
1.59×
Q3 25
Q2 25
Q1 25
Q4 24
0.10×
1.17×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MDXG
MDXG
PAMT
PAMT
Operating Cash FlowLast quarter
$25.0M
$-5.8M
Free Cash FlowOCF − Capex
$-25.0M
FCF MarginFCF / Revenue
-17.7%
Capex IntensityCapex / Revenue
13.6%
Cash ConversionOCF / Net Profit
1.64×
TTM Free Cash FlowTrailing 4 quarters
$-23.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MDXG
MDXG
PAMT
PAMT
Q4 25
$25.0M
$-5.8M
Q3 25
$29.3M
$5.9M
Q2 25
$14.4M
$12.2M
Q1 25
$5.3M
$5.0M
Q4 24
$18.8M
$15.2M
Q3 24
$19.6M
$15.5M
Q2 24
$21.8M
$18.7M
Q1 24
$6.0M
$9.6M
Free Cash Flow
MDXG
MDXG
PAMT
PAMT
Q4 25
$-25.0M
Q3 25
$2.5M
Q2 25
$5.9M
Q1 25
$-6.8M
Q4 24
$-39.9M
Q3 24
$-33.6M
Q2 24
$4.1M
Q1 24
$-12.2M
FCF Margin
MDXG
MDXG
PAMT
PAMT
Q4 25
-17.7%
Q3 25
1.7%
Q2 25
3.9%
Q1 25
-4.4%
Q4 24
-24.0%
Q3 24
-18.4%
Q2 24
2.2%
Q1 24
-6.7%
Capex Intensity
MDXG
MDXG
PAMT
PAMT
Q4 25
13.6%
Q3 25
2.3%
Q2 25
4.2%
Q1 25
7.6%
Q4 24
33.1%
Q3 24
26.9%
Q2 24
8.0%
Q1 24
12.0%
Cash Conversion
MDXG
MDXG
PAMT
PAMT
Q4 25
1.64×
Q3 25
1.75×
Q2 25
1.50×
Q1 25
0.75×
Q4 24
2.53×
Q3 24
2.42×
6.44×
Q2 24
1.24×
Q1 24
0.65×
34.11×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MDXG
MDXG

Wound$78.7M67%
Surgical$39.4M33%

PAMT
PAMT

Freight Transportation Service$123.1M87%
Fuel Surcharge$18.2M13%

Related Comparisons